Aldeyra Therapeutics
ALDXAldeyra Therapeutics is a biotechnology company focused on developing innovative therapies for immune-mediated diseases by modulating protein systems rather than directly inhibiting single targets.
Earnings
Next report
Nov 4, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
Aldeyra Therapeutics is a biotechnology company focused on developing innovative therapies for immune-mediated diseases by modulating protein systems rather than directly inhibiting single targets. Their primary approach utilizes RASP (reactive aldehyde species) modulators to optimize multiple inflammatory pathways simultaneously while minimizing toxicity. The company's late-stage pipeline targets significant unmet needs in ophthalmology, specifically dry eye disease and allergic conjunctivitis.
A pioneer in RASP modulation technology with a first-in-class product candidate in late-stage clinical trials for dry eye disease.
FAQ
- What is Aldeyra Therapeutics's market cap?
- Aldeyra Therapeutics (ALDX) has a market capitalization of $94.1M and trades on NASDAQ.
- Who are Aldeyra Therapeutics's competitors?
- Aldeyra Therapeutics's key competitors include Regeneron Pharmaceuticals, Inc., Bausch + Lomb, Johnson & Johnson, and others. These companies compete in similar markets and product categories.
- Who does Aldeyra Therapeutics partner with?
- Aldeyra Therapeutics's notable partners include AbbVie Inc., Massachusetts Eye and Ear Infirmary.
- What subsidiaries does Aldeyra Therapeutics have?
- Aldeyra Therapeutics's subsidiaries include Helio Vision, Inc..
- Where is Aldeyra Therapeutics headquartered?
- Aldeyra Therapeutics is headquartered in United States of America and employs approximately 10 people. It has been publicly traded since 2014.